A systematic review of the role of inflammatory biomarkers in acute, subacute and chronic non-specific low back pain.
CRP
Central sensitization
IL-1β
IL-6
Inflammatory biomarkers
Non-specific low back pain
Systematic review
TNF-α
Journal
BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565
Informations de publication
Date de publication:
03 Mar 2020
03 Mar 2020
Historique:
received:
31
01
2020
accepted:
21
02
2020
entrez:
5
3
2020
pubmed:
5
3
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Low back pain (LBP) is one of the greatest contributors to disability in the world and there is growing interest on the role of biomarkers in LBP. To purpose of this review was to analyze available evidence on the relationship between inflammatory biomarkers, clinical presentation, and outcomes in patients with acute, subacute and chronic non-specific low back pain (NSLBP). A search was performed in Medline, Embase, Cinahl and Amed databases. Studies which measured levels of inflammatory biomarkers in participants with NSLBP were included. Two reviewers independently screened titles and abstracts, full-texts, and extracted data from included studies. Methodological quality was assessed using the Newcastle Ottawa Quality Assessment Scale. Level of evidence was assessed using the modified GRADE approach for prognostic studies. Seven primary studies were included in this review. All results assessed using the modified GRADE demonstrated low to very low quality evidence given the small number of studies and small sample. Three studies examined C-reactive protein (CRP), one of which found significantly higher CRP levels in an acute NSLBP group than in controls and an association between high pain intensity and elevated CRP. Three studies examined tumor necrosis factor alpha (TNF-α), two of which found elevated TNF-α in chronic NSLBP participants compared to controls. Two studies examined interleukin 6 (IL-6), none of which found a significant difference in IL-6 levels between NSLBP groups and controls. Two studies examined interleukin 1 beta (IL-β), none of which found a significant difference in IL-β levels between NSLBP groups and controls. This review found evidence of elevated CRP in individuals with acute NSLBP and elevated TNF-Α in individuals with chronic NSLBP. There are a limited number of high-quality studies evaluating similar patient groups and similar biomarkers, which limits the conclusion of this review.
Sections du résumé
BACKGROUND
BACKGROUND
Low back pain (LBP) is one of the greatest contributors to disability in the world and there is growing interest on the role of biomarkers in LBP. To purpose of this review was to analyze available evidence on the relationship between inflammatory biomarkers, clinical presentation, and outcomes in patients with acute, subacute and chronic non-specific low back pain (NSLBP).
METHODS
METHODS
A search was performed in Medline, Embase, Cinahl and Amed databases. Studies which measured levels of inflammatory biomarkers in participants with NSLBP were included. Two reviewers independently screened titles and abstracts, full-texts, and extracted data from included studies. Methodological quality was assessed using the Newcastle Ottawa Quality Assessment Scale. Level of evidence was assessed using the modified GRADE approach for prognostic studies.
RESULTS
RESULTS
Seven primary studies were included in this review. All results assessed using the modified GRADE demonstrated low to very low quality evidence given the small number of studies and small sample. Three studies examined C-reactive protein (CRP), one of which found significantly higher CRP levels in an acute NSLBP group than in controls and an association between high pain intensity and elevated CRP. Three studies examined tumor necrosis factor alpha (TNF-α), two of which found elevated TNF-α in chronic NSLBP participants compared to controls. Two studies examined interleukin 6 (IL-6), none of which found a significant difference in IL-6 levels between NSLBP groups and controls. Two studies examined interleukin 1 beta (IL-β), none of which found a significant difference in IL-β levels between NSLBP groups and controls.
CONCLUSIONS
CONCLUSIONS
This review found evidence of elevated CRP in individuals with acute NSLBP and elevated TNF-Α in individuals with chronic NSLBP. There are a limited number of high-quality studies evaluating similar patient groups and similar biomarkers, which limits the conclusion of this review.
Identifiants
pubmed: 32126991
doi: 10.1186/s12891-020-3154-3
pii: 10.1186/s12891-020-3154-3
pmc: PMC7055034
doi:
Substances chimiques
Biomarkers
0
Inflammation Mediators
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
142Références
Am J Phys Med Rehabil. 2017 Aug;96(8):535-540
pubmed: 27898478
Arthritis Rheum. 2012 Jun;64(6):2028-37
pubmed: 22231424
Ann Rheum Dis. 2005 Jun;64(6):921-5
pubmed: 15897311
Eur Spine J. 2006 Mar;15 Suppl 2:S169-91
pubmed: 16550447
Syst Rev. 2013 Sep 05;2:71
pubmed: 24007720
Spine (Phila Pa 1976). 2003 Jun 15;28(12):1290-9
pubmed: 12811274
PLoS One. 2016 Jan 25;11(1):e0147601
pubmed: 26808317
Pain. 2011 Mar;152(3 Suppl):S2-15
pubmed: 20961685
Neurosci Lett. 2004 May 6;361(1-3):184-7
pubmed: 15135924
N Engl J Med. 2001 Feb 1;344(5):363-70
pubmed: 11172169
Spine J. 2018 Nov;18(11):2140-2151
pubmed: 29960111
Lancet. 2017 Feb 18;389(10070):736-747
pubmed: 27745712
Arthritis Res Ther. 2010;12(5):R186
pubmed: 20937109
Ann N Y Acad Sci. 2017 Dec;1410(1):68-84
pubmed: 29265416
Lancet. 2017 Sep 16;390(10100):1211-1259
pubmed: 28919117
Clin J Pain. 2008 Mar-Apr;24(3):273-8
pubmed: 18287835
Spine (Phila Pa 1976). 2002 Nov 1;27(21):2409-16
pubmed: 12438991
J Neurosci. 2008 May 14;28(20):5189-94
pubmed: 18480275
J Bone Joint Surg Am. 2006 Apr;88 Suppl 2:21-4
pubmed: 16595438
J Neuroinflammation. 2016 May 04;13(1):100
pubmed: 27145808
Curr Rev Musculoskelet Med. 2015 Mar;8(1):18-31
pubmed: 25694233
Eur Spine J. 2018 Apr;27(4):763-777
pubmed: 29460011
Lancet. 2011 Oct 29;378(9802):1560-71
pubmed: 21963002
Emerg Med J. 2003 Jan;20(1):54-60
pubmed: 12533370
Lancet. 1999 Aug 14;354(9178):581-5
pubmed: 10470716
Clin J Pain. 2011 Jan;27(1):35-41
pubmed: 21188850
Eur J Pain. 2006 Nov;10(8):711-9
pubmed: 16403662
Spine (Phila Pa 1976). 2016 Feb;41(3):197-203
pubmed: 26571172
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
J Back Musculoskelet Rehabil. 2016 Nov 21;29(4):625-633
pubmed: 27062464
Biochem Biophys Res Commun. 2007 Feb 9;353(2):217-24
pubmed: 17184730
Brain Behav Immun. 2017 Feb;60:84-92
pubmed: 27720935
J Back Musculoskelet Rehabil. 2015;28(2):343-9
pubmed: 25271196
BMJ. 2009 Jun 04;338:b1805
pubmed: 19502217